Evercore analyst Liisa Bayko maintains $Travere Therapeutic (TVTX.US)$ with a buy rating, and adjusts the target price from $12 to $30.
According to TipRanks data, the analyst has a success rate of 42.7% and a total average return of 9.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Travere Therapeutic (TVTX.US)$'s main analysts recently are as follows:
After discussions with an attending nephrologist post-PARASOL Scientific Workshop, there is a reported enthusiasm for utilizing proteinuria as the primary endpoint in clinical studies. Should this approach receive regulatory adoption, it could have favorable implications for Filspari. The consideration of focal segmental glomerulosclerosis (FSGS) has been reintroduced into forecasting models with a cautious projection of a 2025 market introduction and a 45% probability of success.
The recent PARASOL workshop meeting was viewed positively for Travere Therapeutics, enhancing the likelihood of FDA approval to expand Filspari into focal segmental glomerulosclerosis (FSGS) based on the existing Phase 3 DUPLEX dataset. Following this meeting, the perceived probability of success for the program has increased, with expectations for program penetration also being revised upwards.
Following the PARASOL Working Group meeting that brought together various stakeholders to discuss focal segmental glomerulosclerosis trial endpoints, it was noted that the FDA is open to exploring alternatives to eGFR as an endpoint in FSGS. Additionally, proteinuria is being considered as a possible validated surrogate endpoint. Expectations are set for Travere to engage with the FDA and potentially submit an sNDA in the first half of 2025. With final results of the PARASOL to be shared at ASN and through a publication, there's a possibility that an approval could enhance Travere's attractiveness for M&A opportunities.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
